DHEA And Anti-Aging MedicineJune 2002
By Ivy Greenwell
The aging process is inextricably tied to a decrease in beneficial hormones, such as growth hormone, thyroid and DHEA, and an increase in hormones whose elevated levels are clearly harmful, such as insulin and cortisol.
The dramatic drop in DHEA levels observed during aging parallels the development of degenerative syndromes such as immunosenescence, atherosclerosis, osteoporosis, cognitive decline, depressed mood and increased risk of cancer. The elderly suffer from a decline in DHEA secretion and a rise in cortisol. Those with very low levels of DHEA and higher levels of cortisol are most likely to suffer from dementia. The neuroprotective effects of DHEA replacement may be the most important anti-aging benefit, since ultimately there is nothing as important as slowing down the aging of the brain.
Can replacing DHEA through oral, sublingual or transdermal route help prevent the degenerative disorders of aging? Is it safe? Research keeps answering these questions in the affirmative. At the same time, the picture is complex. DHEA appears to be metabolized differently in men than in women, and consequently have somewhat different effects. It may be more crucial to men for cardiovascular protection, yet the antidepressant effect may be stronger for women, who are also more likely to report an increase in libido, and show improvement in skin thickness and bone mass. Interestingly, the rise in serum estradiol and testosterone is more commonly seen in women (Legrain 2000; Baulieu 2000). At this point, the majority of studies point to anti-aging benefits of DHEA replacement that simply cannot be ignored.
Hormone replacement for older men and postmenopausal women
"Andropause," also referred to as "partial androgen deficiency in the aging male," is characterized by symptoms such as decline in muscle mass and strength, increase in body fat, especially around the abdomen, dry skin, reduction in libido, fatigue, loss of bone mass and mood disorders such as depression and apathy. The simple answer seems to be testosterone and DHEA replacement. Mainstream physicians are slowly beginning to accept the need for testosterone replacement, but most are still unaware of the need to replace DHEA as well.
One of the most exciting studies on the importance of DHEA for older men was published by Morley (1997). Morley found that bioavailable testosterone (also known as "free testosterone," meaning testosterone not bound to sex hormone binding-globulin [SHBG]), correlated best with various markers of physical and cognitive function. DHEA, in turn, correlated well with the levels of bioavailable testosterone. It is well known that both free testosterone and DHEA dramatically decline with aging. It is also known that DHEA can be easily converted to testosterone, and in that sense DHEA and its sulfated form serve as precursors for testosterone. But the values obtained in this study indicated a larger involvement of DHEA in the regulation of the levels of free testosterone. As Morley puts it, "The rate of decrease in bioavailable testosterone paralleled almost exactly that of DHEA." Free testosterone travels in the bloodstream bound to albumin, a protein in the serum that can serve as a carrier for various substances needed by the tissues. Morley suggests that DHEA facilitates the binding of testosterone to albumin. If this hypothesis is correct, then DHEA would be a very welcome addition to testosterone replacement. Total testosterone does not decline as rapidly with aging in men; it is the loss of free testosterone that is crucial. The right dose of DHEA would presumably increase both DHEA and the delivery of free testosterone to tissue receptors.
Several other studies have confirmed the benefits of DHEA replacement. For instance, a Czech study investigated the effects of transdermal DHEA (50 mg in gel) on men of various ages (mean age 52). The authors found that dermal DHEA was well absorbed and quickly converted to DHEA-S, androstenedione, and then the estrogenic and androgenic metabolites, including estradiol and testosterone. Negative correlations were found between DHEA and lipoprotein (a), DHEA-S and cholesterol, and DHEA, DHEA-S, testosterone and triglycerides. In other words, as DHEA levels rose, the levels of various serum lipids went down in a way that indicated cardioprotective benefits. There was, however, a decrease in endogenous DHEA. Because of the brief duration of the study, the main conclusion that can be drawn is that the transdermal route of DHEA application (gel) does significantly increase the levels of those steroids that are the metabolites of DHEA.
DHEA supplementation may be of most help to both men and women over 70, since their natural production has usually suffered a profound decline by that age. A recent study investigated the effects of 50 mg oral DHEA per day for six months on men and women between the ages of 72 and 74. In response to DHEA replacement, both sexes showed an increase in bone mineral density, both total and in lumbar spine, and an overall increase in lean body mass combined with a decrease in fat mass. DHEA replacement also resulted in increased IGF-1 and total testosterone. At the same time, a small placebo-controlled pilot study at a University of Vienna impotence clinic found that supplementation with 50 mg DHEA resulted in an improvement in erectile function without an increase in PSA or prostate volume. Such findings indicate that DHEA replacement can at least partly reverse aging-related changes in the elderly, increasing the sense of well-being and sexual function.
Speaking of the prostate, the fear that is often raised when it comes to any androgen replacement is the possibility of increased risk of prostate cancer. Some unexpected findings in animal studies suggest that starting DHEA treatment early may in fact help prevent prostate cancer. In a study by McCormick and Rao (1999), rats treated with DHEA prior to exposure to carcinogen appeared to be resistant to developing prostate cancer. As the authors state, "DHEA inhibits prostate cancer induction both when chronic administration is begun prior to carcinogen exposure, and when administration is delayed until preneoplastic prostate lesions are present." While retinoic acid turned out to be the most potent inhibitor of prostate cancer induction, DHEA produced sufficiently dramatic results to make the authors name both retinoic acid and DHEA as "the most active agents" for the chemoprevention of prostate cancer.
Another study by Rao confirmed that, "nontoxic doses of DHEA confer significant protection against prostate carcinogenesis in rats." Furthermore, the findings indicate that DHEA is effective also in later stages of induction and can inhibit the progression of precancerous lesions to invasive cancer. We do know that DHEA may help prevent certain kinds of cancer. Likewise, some holistic physicians believe that if androgen replacement is started early enough, both DHEA and testosterone actually help prevent prostate cancer (although as a precaution, holistic physicians also recommend supplements such as zinc, saw-palmetto, omega-3 fatty acids, lycopene and flavonoids [green tea, soy], as well as regular exercise). More research is obviously needed. For now, we have the findings of one in-vitro study using culture prostate cancer cells, showing that while the so-called "strong form" of testosterone, dihydrotestosterone (DHT) stimulated cell growth, DHEA had no effect. Likewise, patients with prostate cancer do not appear to have higher DHEA levels than healthy controls, as confirmed by a recent study done at the University of Vienna (Schatzl 2000). Nevertheless, it is too early to make any firm statements about DHEA and the risk of prostate cancer. (Note of caution: Our knowledge is incomplete, and it is better to err on the side of caution. Men diagnosed with prostate cancer should not take DHEA.)
pilot study at a University
of Vienna impotence clinic
found that supplementation
with 50 mg DHEA resulted
in an improvement in erectile
function without an increase
in PSA or prostate volume.
Because of the risks involved in the mainstream hormone replacement therapy for postmenopausal women, scientists have turned their attention to DHEA as a possible alternative. Several studies have explored the effects of short-term treatment with DHEA on postmenopausal women. It is worth noting that while in men the levels of DHEA decline in a linear fashion, in women there is a dramatic 40% fall during the sixth decade, reflecting menopause. This is due to the fact that a portion of women's DHEA is produced by the ovaries. After menopause the ovarian production of androgens normally diminishes or even ceases with ovarian atrophy. Recent findings from the Rancho Bernardo Study indicate that women in the 50 to 89 age range have lower levels of DHEA than men and, what is potentially more worrisome, a higher cortisol/DHEA-S ratio. The latter may be related to women's higher risk for osteoporosis and decline in brain function, including greater susceptibility to depression and Alzheimer's disease.
There is a special interest in the ability of DHEA to improve the sense of well-being in postmenopausal women. This effect appears to correlate with the rise in the levels of circulating beta endorphins, known to decline with menopause. One recent Italian study compared women taking 50 mg of DHEA sulfate with women using the low-dose (50 micrograms) estradiol patch, and women taking both DHEA sulfate and using the low-dose estradiol patch. All three groups showed a similar improvement in the levels of beta endorphins and a decrease in menopausal symptoms. The group receiving DHEA or DHEA plus the estradiol patch also showed higher levels of DHEA, DHEA-S, androstenedione and testosterone. In addition, the group receiving either estradiol alone or the combined therapy also showed increased levels of estradiol, estrone and growth hormone. The ability of DHEA supplementation to increase the levels of androgens argues for the desirability of the combined therapy, since it restores a more balanced endocrine profile.
Another Italian study investigated the effects of 50 mg DHEA on postmenopausal women according to their age (50 to 55 for early postmenopause versus 60 to 65 for late postmenopause) and weight (normal versus overweight, BMI 26 to 30). The study found an increase in DHEA, DHEA-S, androstenedione, testosterone and dihydrotestosterone in all women. The levels of sex hormone-binding globulin decreased only in women who were older and overweight. All groups showed a three-fold rise in beta endorphins, together with an increase in allopregnanolone (a neurosteroid with a calming effect). In addition, all groups showed a drop in cortisol and gonadotropins. Younger women experienced an improvement in menopausal symptoms. There was no effect on uterine endometrium, which is good news for those women who are bothered by breakthrough bleeding when using mainstream-type hormone replacement therapy.
The antidepressant effect may be the best news of all. A separate study by the same team of investigators found a significant increase in plasma beta-endorphin levels in women using 100 mg of oral DHEA. The authors hypothesize that DHEA could enhance the sense of well-being by restoring neuroendocrine control of beta-endorphin secretion by the pituitary.
ability of DHEA to improve the
sense of well-being in
postmenopausal women. This
effect appears to correlate with
the rise in the levels of circulating
beta endorphins, known to
decline with menopause.
A German study, likewise using 50 mg oral DHEA, found similar effects in women with initial DHEA deficiency due to adrenal hypofunction. The serum levels of DHEA, androstenedione and testosterone rose into the normal range; sex hormone-binding globulin decreased. The women reported improved overall sense of well-being, less anxiety and depression, less obsessive-compulsive behavior, stronger libido and more sexual satisfaction. One negative effect was a lowering of HDL cholesterol. Minor side effects included increased oiliness of the skin and scalp hair, acne, more sweating, and increased growth of facial and body hair (on the forearms, for instance), the coarsening and darkening of facial and body hair, and deepening of the voice. These side effects are androgenic in nature, that is, related to male hormones, especially dihydrotestosterone (DHT). The most prevalent side effect of DHEA replacement in women is simply acne, which some women find mild enough to control with a topical lotion.
Unfortunately, it is very difficult to control the way the body chooses to convert DHEA. In women (but not in men), both testosterone and its stronger form, DHT, usually go up considerably when DHEA is taken; in fact, DHT levels can triple. One solution is to lower the dose. Women naturally produce less DHEA than men, and their replacement dose should be lower than for men. Some holistic physicians recommend no more than 25 mg of DHEA every other day. Men do not seem to have any side effects when taking even large doses of DHEA, although there have been some anecdotal reports of elderly, testosterone-deficient men developing acne. One theory is that in women (i.e. in predominantly estrogenic milieu), the conversion of DHEA is mainly androgenic, while in men (i.e. in predominantly androgenic milieu), it's mainly estrogenic. More research on the metabolism of DHEA is needed before the question of sex differences can be settled.
The repeated finding of improved well-being in women on DHEA replacement is especially interesting in light of the Rancho Bernardo Study findings that low DHEA, but not the deficiency of other sex hormones, correlates with depression in older women. A Japanese study similarly found a significant inverse correlation between mood and DHEA levels, but not between mood and other steroids.